Related Experiment Video
Updated: Sep 26, 2025

10:14
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
3.7K
Genetic Testing of Inherited Retinal Disease in Australian Private Tertiary Ophthalmology Practice
Sena A Gocuk1, Yuanzhang Jiao2, Alexis Ceecee Britten-Jones1,3,4
1Department of Optometry and Vision Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Clinical Ophthalmology (Auckland, N.Z.)
|April 21, 2022
Summary
Genetic testing for inherited retinal diseases (IRDs) is underutilized in Australian private practice, with only 9.5% of patients tested. Younger patients and those with longer care durations were more likely to undergo testing, highlighting potential barriers to access.
Area of Science:
- Ophthalmology
- Genetics
- Medical Diagnostics
Background:
- Inherited retinal diseases (IRDs) are a diverse group of genetic disorders affecting vision.
- Genetic testing is crucial for diagnosing IRDs and guiding management.
- Assessing the current utilization of genetic testing in IRD patient care is important.
Purpose of the Study:
- To evaluate the prevalence and uptake of genetic testing for inherited retinal diseases (IRDs) within a tertiary private practice in Australia.
- To identify factors associated with genetic testing in IRD patients.
- To understand barriers to genetic testing in IRD diagnosis.
Main Methods:
- Retrospective analysis of 464 patient records with diagnosed or suspected IRDs.
- Categorization of IRDs into specific types (e.g., panretinal pigmentary retinopathies, macular dystrophies).
- Review of genetic testing status, inheritance patterns, and reasons for non-testing.
Main Results:
- Only 9.5% of patients had available genetic testing results.
- Younger patients (<45 years) and those with longer care (>12 months) were more likely to have genetic testing.
- Common reasons for not undergoing testing included awaiting appointments or patient refusal; 69.2% of records lacked documentation of testing status.
Conclusions:
- The uptake of genetic testing for IRDs in this Australian private practice cohort is low, potentially due to historical practices and accessibility issues.
- Increasing recognition of IRD genetic testing's importance is expected to drive future changes in patient management and testing rates.
- Further research is needed to address clinician and patient barriers to improve genetic testing rates for IRDs.

